Pooling Canadian innovation efforts to make breakthrough discoveries

Posted: May 13, 2021

Dr. Chris Cairo from the University of Alberta (left) and Dr. Alexey Pshezhetsky at the Sainte-Justine Health Centre (right) are the lead investigators probing the connection between glycans and autoimmune diseases, such as ITP. (Photo: Richard Siemens and GlycoNet)

The Alberta-based Réseau Canadien de la Glycomique (GlycoNet), which develops new carbohydrate-based drugs, vaccines and diagnostics, joined forces with Quebec-based IRICoR, a group that specializes in drug discovery and commercialization. Both are part of Canada’s Networks of Centres of Excellence program, which fosters academic, government and industry partnerships in various areas of research.

GlycoNet and IRICoR are currently working together to tackle immune thrombocytopenia, formerly known as idiopathic thrombocytopenic purpura (ITP), a rare blood disorder that causes the immune system to attack – and destroy – otherwise normal platelets.

Read the full story on The Globe and Mail: Scientific collaboration yields new hope for children affected by rare blood disorder

Discover more from GlycoNet News.

© Réseau Canadien de la Glycomique (GlycoNet). Tous droits réservés.

fr_CAFrench
Scroll to Top